We are live on ! Find out more
TGTX icon

TG Therapeutics

197 hedge funds and large institutions have $1.11B invested in TG Therapeutics in 2022 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 64 increasing their positions, 57 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 25

51% more call options, than puts

Call options by funds: $79.4M | Put options by funds: $52.5M

12% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 57

8% more funds holding

Funds holding: 183 → 197 (+14)

4.73% less ownership

Funds ownership: 68.97% → 64.24% (-4.7%)

30% less capital inflows, than outflows

Capital inflows: $98.1M | Capital outflows: $140M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
197
Holders Change
+14
Holders Change %
+7.65%
% of All Funds
3.15%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
40
Increased
64
Reduced
57
Closed
25
Calls
$79.4​M
Puts
$52.5​M
Net Calls
+$26.9​M
Net Calls Change
-⁠$3.01​M

TGTX Hedge Fund Activity: Q4 2022 in Review

197 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2022, worth a combined $1.11B — up 87% from $595M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new TGTX positions and 25 closed out — a net gain of 15 holders — while 64 added to existing stakes and 57 trimmed.

The largest buyer was Millennium Management, adding an estimated $16.2M. The largest seller was Maverick Capital, cutting an estimated $24.6M.

  • 197 institutional investors held TG Therapeutics (TGTX) as of Q4 2022, up from 183 in Q3 2022.
  • Funds reported $1.11B of TG Therapeutics stock for Q4 2022, up 87% quarter-over-quarter.
  • 40 funds opened new TG Therapeutics positions in Q4 2022 and 25 closed out, a net change of +15 holders.
  • The largest TG Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $16.2M added.
  • The largest TG Therapeutics seller in Q4 2022 was Maverick Capital, an estimated $24.6M sold.

Based on aggregated 13F filings for Q4 2022.